Europe Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe liver cancer diagnostics market is projected to register a substantial CAGR of 6.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe ) - Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe liver cancer diagnostics market are:

Government initiatives toward liver cancer diagnostics

Rise in diagnostic product approvals

Market Players:

Some of the major players operating in the Europe liver cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Koninklijke Philips N.V.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Agilent Technologies, Inc.

Illumina, Inc.

QIAGEN

FUJIFILM Corporation

Sysmex Corporation AB

Scitex Pte Ltd. (Subsidiary of Danaher.)

Epigenomics AG

Tebubio

Fujirebio

Diagnostic Biosystems Inc.

Q-LINE BIOTECH PVT LTD.

MOLGEN

BIOCEPT, INC.

Boditech Med Inc.

Elabscience Biotechnology Inc.

Hipro Biotechnology Co., Ltd.

Altogen Biosystems

Tosoh India Pvt. Ltd.

ABK Biomedical Inc.

Diazyme Laboratories, Inc.

1 INTRODUCTION 55

1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58

2 MARKET SEGMENTATION 61

2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

4 PREMIUM INSIGHTS 77

4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80

5 EUROPE LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81

6 INDUSTRY INSIGHTS 85

7 MARKET OVERVIEW 87

7.1 DRIVERS 89
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
- 7.1.3 INCREASING CASES OF LIVER CANCER 92
- 7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
- 7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
- 7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
- 7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
- 7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
- 7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99

8 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100

8.1 OVERVIEW 101
8.2 IMAGING TEST 104
- 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
  - 8.2.1.1 MR ANGIOGRAPHY (MRA) 105
  - 8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
- 8.2.2 COMPUTED TOMOGRAPHY 106
- 8.2.3 POSITRON EMISSION TOMOGRAPHY 106
- 8.2.4 ULTRASOUND 106
- 8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
- 8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
- 8.4.2 CORE NEEDLE BIOPSY 108
- 8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109

9 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110

9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118

10 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119

10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
- 10.2.1 HEMANGIOMA 124
- 10.2.2 HEPATIC ADENOMA 124
- 10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
- 10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
- 10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
- 10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
- 10.3.4 HEPATOBLASTOMA 126

11 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127

11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
- 11.2.1 NEXT GENERATION SEQUENCING 132
- 11.2.2 MICROARRAYS 132
- 11.2.3 PCR 132
- 11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
- 11.3.1 IMAGING 133
- 11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
- 11.4.1 ELISA TEST KITS 135
- 11.4.2 CASSETTE TEST KITS 135
- 11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135

12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136

12.1 OVERVIEW 137
12.2 SCREENING 140
- 12.2.1 PLATFORM BASED PRODUCTS 141
- 12.2.2 INSTRUMENT BASED PRODUCTS 141
- 12.2.3 KITS AND REAGENTS 141
- 12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
- 12.3.1 PLATFORM BASED PRODUCTS 142
- 12.3.2 INSTRUMENT BASED PRODUCTS 142
- 12.3.3 KITS AND REAGENTS 142
- 12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
- 12.4.1 PLATFORM BASED PRODUCTS 144
- 12.4.2 INSTRUMENT BASED PRODUCTS 144
- 12.4.3 KITS AND REAGENTS 144
- 12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
- 12.5.1 PLATFORM BASED PRODUCTS 146
- 12.5.2 INSTRUMENT BASED PRODUCTS 146
- 12.5.3 KITS AND REAGENTS 146
- 12.5.4 OTHER CONSUMABLES 146

13 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147

13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156

14 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157

14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162

15 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163

15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172

16 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173

16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179

17 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180

17.1 EUROPE 181
- 17.1.1 GERMANY 194
- 17.1.2 FRANCE 202
- 17.1.3 RUSSIA 210
- 17.1.4 ITALY 217
- 17.1.5 U.K. 225
- 17.1.6 SPAIN 232
- 17.1.7 TURKEY 239
- 17.1.8 NETHERLANDS 246
- 17.1.9 BELGIUM 254
- 17.1.10 SWITZERLAND 262
- 17.1.11 REST OF EUROPE 270

18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 271

18.1 COMPANY SHARE ANALYSIS: EUROPE 271

19 SWOT ANALYSIS 272

20 COMPANY PROFILE 273

20.1 F. HOFFMANN-LA ROCHE LTD. 273
- 20.1.1 COMPANY SNAPSHOT 273
- 20.1.2 REVENUE ANALYSIS 273
- 20.1.3 COMPANY SHARE ANALYSIS 274
- 20.1.4 PRODUCT PORTFOLIO 274
- 20.1.5 RECENT DEVELOPMENT 274
20.2 KONINLIJKE PHILIPS N.V. 275
- 20.2.1 COMPANY SNAPSHOT 275
- 20.2.2 REVENUE ANALYSIS 275
- 20.2.3 COMPANY SHARE ANALYSIS 276
- 20.2.4 PRODUCT PORTFOLIO 276
- 20.2.5 RECENT DEVELOPMENT 276
20.3 THERMO FISHER SCIENTIFIC INC. 277
- 20.3.1 COMPANY SNAPSHOT 277
- 20.3.2 REVENUE ANALYSIS 277
- 20.3.3 COMPANY SHARE ANALYSIS 278
- 20.3.4 PRODUCT PORTFOLIO 278
- 20.3.5 RECENT DEVELOPMENT 278
20.4 BD 279
- 20.4.1 COMPANY SNAPSHOT 279
- 20.4.2 REVENUE ANALYSIS 279
- 20.4.3 COMPANY SHARE ANALYSIS 280
- 20.4.4 PRODUCT PORTFOLIO 280
- 20.4.5 RECENT DEVELOPMENTS 281
20.5 SIEMENS HEALTHCARE GMBH 282
- 20.5.1 COMPANY SNAPSHOT 282
- 20.5.2 REVENUE ANALYSIS 282
- 20.5.3 COMPANY SHARE ANALYSIS 283
- 20.5.4 PRODUCT PORTFOLIO 283
- 20.5.5 RECENT DEVELOPMENT 283
20.6 AGILENT TECHNOLOGIES, INC. 284
- 20.6.1 COMPANY SNAPSHOT 284
- 20.6.2 REVENUE ANALYSIS 284
- 20.6.3 PRODUCT PORTFOLIO 285
- 20.6.4 RECENT DEVELOPMENTS 285
20.7 ABK BIOMEDICAL INC. 286
- 20.7.1 COMPANY SNAPSHOT 286
- 20.7.2 PRODUCT PORTFOLIO 286
- 20.7.3 RECENT DEVELOPMENT 286
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 287
- 20.8.1 COMPANY SNAPSHOT 287
- 20.8.2 REVENUE ANALYSIS 287
- 20.8.3 PRODUCT PORTFOLIO 288
- 20.8.4 RECENT DEVELOPMENT 288
20.9 ALTOGEN BIOSYSTEMS 289
- 20.9.1 COMPANY SNAPSHOT 289
- 20.9.2 PRODUCT PORTFOLIO 289
- 20.9.3 RECENT DEVELOPMENT 289
20.10 BIOCEPT, INC. 290
- 20.10.1 COMPANY SNAPSHOT 290
- 20.10.2 REVENUE ANALYSIS 290
- 20.10.3 PRODUCT PORTFOLIO 291
- 20.10.4 RECENT DEVELOPMENT 291
20.11 BODITECH MED INC. 292
- 20.11.1 COMPANY SNAPSHOT 292
- 20.11.2 PRODUCT PORTFOLIO 292
- 20.11.3 RECENT DEVELOPMENTS 292
20.12 DIAGNOSTIC BIOSYSTEMS INC. 293
- 20.12.1 COMPANY SNAPSHOT 293
- 20.12.2 PRODUCT PORTFOLIO 293
- 20.12.3 RECENT DEVELOPMENT 293
20.13 DIAZYME LABORATORIES, INC. 294
- 20.13.1 COMPANY SNAPSHOT 294
- 20.13.2 PRODUCT PORTFOLIO 294
- 20.13.3 RECENT DEVELOPMENT 294
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 295
- 20.14.1 COMPANY SNAPSHOT 295
- 20.14.2 PRODUCT PORTFOLIO 295
- 20.14.3 RECENT DEVELOPMENT 295
20.15 EPIGENOMICS AG 296
- 20.15.1 COMPANY SNAPSHOT 296
- 20.15.2 REVENUE ANALYSIS 296
- 20.15.3 PRODUCT PORTFOLIO 297
- 20.15.4 RECENT DEVELOPMENT 297
20.16 FUJIFILM CORPORATION 298
- 20.16.1 COMPANY SNAPSHOT 298
- 20.16.2 REVENUE ANALYSIS 298
- 20.16.3 PRODUCT PORTFOLIO 299
- 20.16.4 RECENT DEVELOPMENT 299
20.17 FUJIREBIO 300
- 20.17.1 COMPANY SNAPSHOT 300
- 20.17.2 PRODUCT PORTFOLIO 300
- 20.17.3 RECENT DEVELOPMENTS 300
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 301
- 20.18.1 COMPANY SNAPSHOT 301
- 20.18.2 PRODUCT PORTFOLIO 301
- 20.18.3 RECENT DEVELOPMENT 301
20.19 ILLUMINA, INC. 302
- 20.19.1 COMPANY SNAPSHOT 302
- 20.19.2 REVENUE ANALYSIS 302
- 20.19.3 PRODUCT PORTFOLIO 303
- 20.19.4 RECENT DEVELOPMENTS 304
20.20 MOLGEN 305
- 20.20.1 COMPANY SNAPSHOT 305
- 20.20.2 PRODUCT PORTFOLIO 305
- 20.20.3 RECENT DEVELOPMENT 305

20.21 QIAGEN 306
- 20.21.1 COMPANY SNAPSHOT 306
- 20.21.2 REVENUE ANALYSIS 306
- 20.21.3 PRODUCT PORTFOLIO 307
- 20.21.4 RECENT DEVELOPMENT 307
20.22 Q-LINE BIOTECH PVT LTD. 308
- 20.22.1 COMPANY SNAPSHOT 308
- 20.22.2 PRODUCT PORTFOLIO 308
- 20.22.3 RECENT DEVELOPMENT 308
20.23 SYSMEX CORPORATION 309
- 20.23.1 COMPANY SNAPSHOT 309
- 20.23.2 REVENUE ANALYSIS 309
- 20.23.3 PRODUCT PORTFOLIO 310
- 20.23.4 RECENT DEVELOPMENT 310
20.24 TEBUBIO 311
- 20.24.1 COMPANY SNAPSHOT 311
- 20.24.2 PRODUCT PORTFOLIO 311
- 20.24.3 RECENT DEVELOPMENT 311
20.25 TOSOH INDIA PVT. LTD. 312
- 20.25.1 COMPANY SNAPSHOT 312
- 20.25.2 PRODUCT PORTFOLIO 312
- 20.25.3 RECENT DEVELOPMENT 312

21 QUESTIONNAIRE 313

22 RELATED REPORTS 317

LIST OF TABLES

TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS 65
TABLE 2 LIVER CANCER RATES 68
TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER 69
TABLE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 78
TABLE 5 EUROPE IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 6 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
TABLE 7 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
TABLE 8 EUROPE GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 9 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 10 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
TABLE 11 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 88
TABLE 13 EUROPE STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 14 EUROPE STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 15 EUROPE STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 16 EUROPE STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 17 EUROPE STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 97
TABLE 19 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 20 EUROPE RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 105
TABLE 24 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 25 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 106
TABLE 26 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 27 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 108
TABLE 28 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 29 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 109
TABLE 30 EUROPE OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 114
TABLE 32 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 33 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 115
TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 117
TABLE 36 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 37 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 119
TABLE 38 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 39 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 120
TABLE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 125
TABLE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
TABLE 42 EUROPE NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
TABLE 43 EUROPE FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
TABLE 44 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
TABLE 45 EUROPE IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 46 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 135
TABLE 48 EUROPE MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
TABLE 49 EUROPE FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 141
TABLE 51 EUROPE HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
TABLE 52 EUROPE DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
TABLE 53 EUROPE CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
TABLE 54 EUROPE AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 55 EUROPE ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
TABLE 56 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
TABLE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 151
TABLE 58 EUROPE DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 152
TABLE 59 EUROPE RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
TABLE 60 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
TABLE 61 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 161
TABLE 62 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 63 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 64 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 162
TABLE 65 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 66 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 163
TABLE 67 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 163
TABLE 68 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 163
TABLE 69 EUROPE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 164
TABLE 70 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 71 EUROPE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 72 EUROPE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 73 EUROPE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 74 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 165
TABLE 75 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 76 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 77 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 78 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 79 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 80 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 167
TABLE 81 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 168
TABLE 82 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
TABLE 83 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 84 GERMANY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 85 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 169
TABLE 86 GERMANY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 87 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 170
TABLE 88 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 170
TABLE 89 GERMANY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 171
TABLE 90 GERMANY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 171
TABLE 91 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
TABLE 92 GERMANY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 93 GERMANY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 94 GERMANY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 95 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 173
TABLE 96 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 173
TABLE 97 GERMANY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
TABLE 98 GERMANY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
TABLE 99 GERMANY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
TABLE 100 GERMANY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
TABLE 101 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 175
TABLE 102 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 175
TABLE 103 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
TABLE 104 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 105 FRANCE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 106 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 177
TABLE 107 FRANCE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 108 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 178
TABLE 109 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 178
TABLE 110 FRANCE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 179
TABLE 111 FRANCE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 179
TABLE 112 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
TABLE 113 FRANCE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 114 FRANCE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 115 FRANCE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 116 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 181
TABLE 117 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 181
TABLE 118 FRANCE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 182
TABLE 119 FRANCE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 182
TABLE 120 FRANCE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 182
TABLE 121 FRANCE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 183
TABLE 122 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 183
TABLE 123 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 183
TABLE 124 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 184
TABLE 125 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
TABLE 126 RUSSIA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
TABLE 127 RUSSIA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 185
TABLE 128 RUSSIA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 186
TABLE 129 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 186
TABLE 130 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 186
TABLE 131 RUSSIA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 187
TABLE 132 RUSSIA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 187
TABLE 133 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 187
TABLE 134 RUSSIA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 188
TABLE 135 RUSSIA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 188
TABLE 136 RUSSIA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 188
TABLE 137 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 189
TABLE 138 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
TABLE 139 RUSSIA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
TABLE 140 RUSSIA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 190
TABLE 141 RUSSIA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 190
TABLE 142 RUSSIA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 190
TABLE 143 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 191
TABLE 144 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 191
TABLE 145 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 191
TABLE 146 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
TABLE 147 ITALY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
TABLE 148 ITALY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 193
TABLE 149 ITALY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 193
TABLE 150 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 193
TABLE 151 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 194
TABLE 152 ITALY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 194
TABLE 153 ITALY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 194
TABLE 154 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 195
TABLE 155 ITALY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 195
TABLE 156 ITALY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 195
TABLE 157 ITALY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 196
TABLE 158 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 196
TABLE 159 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 196
TABLE 160 ITALY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 197
TABLE 161 ITALY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 197
TABLE 162 ITALY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 197
TABLE 163 ITALY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 198
TABLE 164 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 198
TABLE 165 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 198
TABLE 166 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 199
TABLE 167 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 168 U.K. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 169 U.K. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 200
TABLE 170 U.K. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
TABLE 171 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 201
TABLE 172 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 201
TABLE 173 U.K. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 202
TABLE 174 U.K. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 202
TABLE 175 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 202
TABLE 176 U.K. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 203
TABLE 177 U.K. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 203
TABLE 178 U.K. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 203
TABLE 179 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 204
TABLE 180 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 204
TABLE 181 U.K. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 204
TABLE 182 U.K. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 205
TABLE 183 U.K. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 205
TABLE 184 U.K. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 205
TABLE 185 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 206
TABLE 186 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 206
TABLE 187 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 206
TABLE 188 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 207
TABLE 189 SPAIN IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 207
TABLE 190 SPAIN MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION) 207
TABLE 191 SPAIN BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 208
TABLE 192 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 208
TABLE 193 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 208
TABLE 194 SPAIN SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 209

LIST OF FIGURES

FIGURE 1 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 35
FIGURE 2 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 38
FIGURE 3 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 39
FIGURE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 40
FIGURE 5 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 40
FIGURE 6 EUROPE LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 41
FIGURE 7 EUROPE LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 43
FIGURE 8 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 45
FIGURE 9 EUROPE LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 46
FIGURE 10 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION 50
FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 51
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030 51
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET 62
FIGURE 14 THE EUROPE MORTALITY RATE DUE TO CANCER 65
FIGURE 15 INCREASING EUROPE CANCER RATE IN 2020 66
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 69
FIGURE 17 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 75
FIGURE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 76
FIGURE 19 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 76
FIGURE 20 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 77
FIGURE 21 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 85
FIGURE 22 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 86
FIGURE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 86
FIGURE 24 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 87
FIGURE 25 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 94
FIGURE 26 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 95
FIGURE 27 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 95
FIGURE 28 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 96
FIGURE 29 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 102
FIGURE 30 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 103
FIGURE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 103
FIGURE 32 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 104
FIGURE 33 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 111
FIGURE 34 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 112
FIGURE 35 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 112
FIGURE 36 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 113
FIGURE 37 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 122
FIGURE 38 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 123
FIGURE 39 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 123
FIGURE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 124
FIGURE 41 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022 132
FIGURE 42 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 133
FIGURE 43 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 133
FIGURE 44 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 134
FIGURE 45 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022 138
FIGURE 46 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 139
FIGURE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 139
FIGURE 48 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 140
FIGURE 49 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 148
FIGURE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 149
FIGURE 51 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 149
FIGURE 52 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 150
FIGURE 53 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 156
FIGURE 54 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 158
FIGURE 55 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 158
FIGURE 56 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 159
FIGURE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 159
FIGURE 58 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 245